In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 530-542

  Cutler, M J ^a,b   Urquhart, B L ^a,b   Velenosi, T J ^a   Meyer Zu Schwabedissen, H E ^c   Dresser, G K ^a   Leake, B F ^d   Tirona, R G ^a,b   Kim, R B ^a,b   Freeman, D J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

dimesna; kidney; Mesna; pharmacokinetics; transporters

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DIMESNA; GLYCOPROTEIN P; MESNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; PROBENECID; PROTEIN MATE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DISPOSITION; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; STEADY STATE;

ADULT; FEMALE; GLOMERULAR FILTRATION RATE; HELA CELLS; HUMANS; KIDNEY; MALE; MEMBRANE TRANSPORT PROTEINS; MESNA; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; PROBENECID; PROTECTIVE AGENTS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84859039113     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011400414     Document Type: Article

References (54)

1. Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol. 1987;5:799-803. (Pubitemid 17120258)
2. Kurowski V, Wagner T. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol. 1997;39: 431-439. (Pubitemid 27078128)
3. Boven E, Westerman M, van Groeningen CJ, et al. Phase Iand pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. Br J Cancer. 2005;92:1636-1643. (Pubitemid 40756473)
4. Verschraagen M, Boven E, Ruijter R, et al. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther. 2003;74: 157-169. (Pubitemid 36951813)
5. Ormstad K, Orrenius S, Lastbom T, et al. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 1983;43:333-338. (Pubitemid 13172838)
6. Urquhart BL, Freeman DJ, Spence JD, House AA. Mesna as anonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis. J Clin Pharmacol. 2007;47:991-997. (Pubitemid 47094103)
7. Brock N, Pohl J, Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol. 1981;100:311-320. (Pubitemid 11051539)
8. Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. Br J Cancer. 2004;90:1654-1659. (Pubitemid 38648252)
9. Millar BC, Millar JL, Clutterbuck R, Jinks S. Studies onthe toxicity of cyclophosphamide in combination with mesna in vitro and in vivo. Cancer Treat Rev. 1983;10(suppl A):63-71. (Pubitemid 14249400)
10. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260-277. (Pubitemid 41254111)
11. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9: 215-236.
12. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008;23:223-235.
13. Ormstad K, Uehara N. Renal transport and disposition of Na-2- mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett. 1982;150:354-358. (Pubitemid 13184074)
14. James CA, Mant TG, Rogers HJ. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol. 1987;23:561-568. (Pubitemid 17087959)
15. Kim KA, Oh SO, Park PW, Park JY. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol. 2005;61:275-280.
16. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006;86:849-899. (Pubitemid 44033384)
17. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010;298:F997-F1005.
18. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27:866-871. (Pubitemid 29347585)
19. Kim RB, Leake B, Cvetkovic M, et al. Modulation bydrugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999;291:1204-1209.
20. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81:362-370. (Pubitemid 46364477)
21. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003;304:223-228. (Pubitemid 36008932)
22. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766-772. (Pubitemid 46580250)
23. Spencer K. Analytical reviews in clinical biochemistry: the estimation of creatinine. Ann Clin Biochem. 1986;23 (pt 1):1-25. (Pubitemid 16178799)
24. Urquhart BL, House AA, Cutler MJ, Spence JD, Freeman DJ. Thiol exchange: anin vitro assay that predicts the efficacy of novel homocysteine lowering therapies. J Pharm Sci. 2006;95:1742-1750. (Pubitemid 44229581)
25. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981;6:135-151.
26. Selen A, Amidon GL, Welling PG. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci. 1982;71: 1238-1242. (Pubitemid 13230064)
27. Mesnex (mesna) injection [product monograph]. Mississauga, Canada: Baxter Healthcare Corporation; 2002.
28. Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos. 2005;33:837-844. (Pubitemid 40686638)
29. Hagenbuch B. Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther. 2010;87:39-47.
30. Ekaratanawong S, Anzai N, Jutabha P, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci. 2004;94:297-304. (Pubitemid 38470739)
31. Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13:866-874. (Pubitemid 34274082)
32. Goren MP, Hsu LC, Li JT. Reduction of dimesna to mesna by the isolated perfused rat liver. Cancer Res. 1998;58:4358-4362. (Pubitemid 28450037)
33. Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatininduced side-effects. Biochem Pharmacol. 2004;68:493-502. (Pubitemid 38887431)
34. Okabe M, Szakacs G, Reimers MA, et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther. 2008;7:3081-3091.
35. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
36. Verschraagen M, Zwiers TH, de Koning PE, Welink J, van der Vijgh WJ. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 2001;753:293-302. (Pubitemid 32217729)
37. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005;102:17923-17928. (Pubitemid 41798478)
38. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81:42-49. (Pubitemid 46050866)
39. Haenisch S, Zimmermann U, Dazert E, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7:56-65. (Pubitemid 46322080)
40. Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80:468-476. (Pubitemid 44737489)
41. Erdman AR, Mangravite LM, Urban TJ, et al. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol. 2006;290: F905-F912. (Pubitemid 43724953)
42. Fujita T, Brown C, Carlson EJ, et al. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics. 2005;15:201-209. (Pubitemid 40569891)
43. Shima JE, Komori T, Taylor TR, et al. Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. Am J Physiol Renal Physiol. 2010;299:F767-F775.
44. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77:17-23. (Pubitemid 40075385)
45. Shaw IC, Weeks MS. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol. 1987;23:933-935. (Pubitemid 17120012)
46. Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res. 1998;4:2313-2320. (Pubitemid 28477894)
47. Verschraagen M, Zwiers TH, Torun E, Donker MG, Reinhoud NJ, van der Vijgh WJ. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector. J Pharm Sci. 2003;92:1040-1050. (Pubitemid 36523450)
48. Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009;11:250-261.
49. Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol. 1990;30:50-56. (Pubitemid 20072725)
50. Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol. 1983;25: 339-345. (Pubitemid 13005579)
51. Vanwert AL, Bailey RM, Sweet DH. Organic anion transporter 3(Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol. 2007;293:F1332-F1341. (Pubitemid 47583969)
52. Li M, Anderson GD, Wang J. Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol. 2006;2:505-532. (Pubitemid 46127070)
53. Eraly SA, Vallon V, Vaughn DA, et al. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem. 2006;281:5072-5083. (Pubitemid 43847773)
54. Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK. Overlapping invitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008;294:F867-F873.